Status:
COMPLETED
Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism
Lead Sponsor:
Bayer
Collaborating Sponsors:
Janssen Scientific Affairs, LLC
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this NIS is to assess in a real-life setting, usage patterns and associated outcomes in the management (healthcare resource utilisation and associated costs) of patients with non-valv...
Eligibility Criteria
Inclusion
- Adult patients ≥ 18 years old with a confirmed diagnosis of non-valvular atrial fibrillation
- Patients must in addition present with at least one of following risk factors:
- prior stroke, TIA (transient ischemic attack) or non-CNS (central nervous system) systemic embolism
- left ventricular ejection fraction of \< 40%
- symptomatic heart failure, New York Heart Association class 2 or higher
- age ≥75 years
- age ≥65 years in combination with either diabetes, coronary disease or arterial hypertension
Exclusion
- Patients who do not fulfil the Belgian reimbursement criteria
Key Trial Info
Start Date :
July 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT01855139
Start Date
July 1 2013
End Date
December 1 2014
Last Update
January 18 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Belgium